Purpose: To study the efficacy of combined use lenvatinib and camrelizumab in hepatocellular carcinoma (HCC) therapy, its impact on disease control rate (DCR).
 Methods: The medical records 92 HCC patients treated at Oncology Department People’s Hospital Dongying, China (April 2019-April 2020), were chosen for analysis, assigned into group (SG, n = 46) reference (RG, based odd even hospita...